In a striking vote of confidence from big pharma, British targeted protein degradation (TPD) specialist Amphista Therapeutics has inked two strategic collaborations with major drug developers.
Bristol Myers Squibb (NYSE: BMY) and Merck KGaA (MRK: DE) will both work with the Cambridge, UK-based firm, leveraging its proprietary Eclipsys TPD platform.
Scientists believe that TPD therapies carry the potential to access many disease targets previously considered “undruggable,” by using physiological mechanisms to remove pathogenic protein from the body.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze